185 related articles for article (PubMed ID: 27087127)
1. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.
Mouchlis VD; Limnios D; Kokotou MG; Barbayianni E; Kokotos G; McCammon JA; Dennis EA
J Med Chem; 2016 May; 59(9):4403-14. PubMed ID: 27087127
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
3. 2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A
Smyrniotou A; Kokotou MG; Mouchlis VD; Barbayianni E; Kokotos G; Dennis EA; Constantinou-Kokotou V
Bioorg Med Chem; 2017 Feb; 25(3):926-940. PubMed ID: 28034646
[TBL] [Abstract][Full Text] [Related]
4. New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2.
Magrioti V; Nikolaou A; Smyrniotou A; Shah I; Constantinou-Kokotou V; Dennis EA; Kokotos G
Bioorg Med Chem; 2013 Sep; 21(18):5823-9. PubMed ID: 23916152
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Yarla NS; Bishayee A; Vadlakonda L; Chintala R; Duddukuri GR; Reddanna P; Dowluru KS
Curr Drug Targets; 2016; 17(16):1940-1962. PubMed ID: 26212262
[TBL] [Abstract][Full Text] [Related]
6. β-Lactones: A Novel Class of Ca
Dedaki C; Kokotou MG; Mouchlis VD; Limnios D; Lei X; Mu CT; Ramanadham S; Magrioti V; Dennis EA; Kokotos G
J Med Chem; 2019 Mar; 62(6):2916-2927. PubMed ID: 30798607
[TBL] [Abstract][Full Text] [Related]
7. Lipidomics-based assays coupled with computational approaches can identify novel phospholipase A
Mouchlis VD; Mu C; Hammons R; Dennis EA
Adv Biol Regul; 2020 May; 76():100719. PubMed ID: 32199750
[TBL] [Abstract][Full Text] [Related]
8. In Silico and In Vitro Study of the Bromelain-Phytochemical Complex Inhibition of Phospholipase A2 (Pla2).
Mohamed Tap F; Abd Majid FA; Ismail HF; Wong TS; Shameli K; Miyake M; Ahmad Khairudin NB
Molecules; 2018 Jan; 23(1):. PubMed ID: 29351216
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A
Nikolaou A; Kokotou MG; Vasilakaki S; Kokotos G
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Jun; 1864(6):941-956. PubMed ID: 30905350
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of bioactive compounds of Clematis gouriana Roxb. ex DC against snake venom phospholipase A
Muthusamy K; Chinnasamy S; Nagarajan S; Sivaraman T; Chinnasamy S
J Biomol Struct Dyn; 2017 Jul; 35(9):1936-1949. PubMed ID: 27355444
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2.
Six DA; Barbayianni E; Loukas V; Constantinou-Kokotou V; Hadjipavlou-Litina D; Stephens D; Wong AC; Magrioti V; Moutevelis-Minakakis P; Baker SF; Dennis EA; Kokotos G
J Med Chem; 2007 Aug; 50(17):4222-35. PubMed ID: 17672443
[TBL] [Abstract][Full Text] [Related]
12. Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.
Vasilakaki S; Barbayianni E; Leonis G; Papadopoulos MG; Mavromoustakos T; Gelb MH; Kokotos G
Bioorg Med Chem; 2016 Apr; 24(8):1683-95. PubMed ID: 26970660
[TBL] [Abstract][Full Text] [Related]
13. Targeting human secretory phospholipase A2 with designed peptide inhibitors for inflammatory therapy.
Wang P; Li Y; Shao Q; Zhou W; Wang K
J Drug Target; 2015 Feb; 23(2):140-6. PubMed ID: 25237841
[TBL] [Abstract][Full Text] [Related]
14. Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Zhan C; Li S; Zhong Q; Zhou D
Chem Biol Drug Des; 2015 Apr; 85(4):418-26. PubMed ID: 25187416
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors.
Lucas KK; Dennis EA
Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):235-48. PubMed ID: 16099408
[TBL] [Abstract][Full Text] [Related]
16. High-affinity selective inhibitor against phospholipase A2 (PLA2): a computational study.
Chinnasamy S; Chinnasamy S; Muthusamy K
J Recept Signal Transduct Res; 2016; 36(2):111-8. PubMed ID: 26422703
[TBL] [Abstract][Full Text] [Related]
17. Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2).
Chinnasamy S; Selvaraj G; Selvaraj C; Kaushik AC; Kaliamurthi S; Khan A; Singh SK; Wei DQ
Int J Biol Macromol; 2020 Feb; 144():53-66. PubMed ID: 31838071
[TBL] [Abstract][Full Text] [Related]
18. Discrete roles of intracellular phospholipases A2 in human neutrophil cytotoxicity.
Mikami S; Aiboshi J; Kobayashi T; Kojima M; Morishita K; Otomo Y
J Trauma Acute Care Surg; 2015 Aug; 79(2):238-46. PubMed ID: 26218692
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel secretory phospholipase A2 inhibitors using virtual screen.
Qiu S; Chen F; Liu Y; Lai L
Chem Biol Drug Des; 2014 Aug; 84(2):216-22. PubMed ID: 24612767
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and functionality in human Group IIA phospholipase A
Kim RR; Malde AK; Nematollahi A; Scott KF; Church WB
Proteins; 2017 May; 85(5):827-842. PubMed ID: 28056488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
